Denali Therapeutics Inc.
DNLI
$20.62
-$0.08-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.63% | 2.01% | 3.24% | 23.81% | 13.45% |
| Gross Profit | -5.63% | -2.01% | -3.57% | -1,157.64% | -1,996.01% |
| SG&A Expenses | 29.52% | 26.98% | 16.02% | 7.99% | 2.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.65% | 6.89% | 5.79% | 0.74% | -6.21% |
| Operating Income | -10.65% | -6.89% | -6.06% | -138.48% | -145.30% |
| Income Before Tax | -21.23% | -16.66% | -14.14% | -230.78% | -191.13% |
| Income Tax Expenses | 50.00% | 126.67% | 126.67% | 126.67% | 126.67% |
| Earnings from Continuing Operations | -21.23% | -16.67% | -14.15% | -230.75% | -191.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.23% | -16.67% | -14.15% | -230.75% | -191.12% |
| EBIT | -10.65% | -6.89% | -6.06% | -138.48% | -145.30% |
| EBITDA | -9.67% | -6.00% | -5.45% | -143.85% | -162.39% |
| EPS Basic | -15.30% | -5.30% | 1.62% | -187.36% | -144.79% |
| Normalized Basic EPS | -7.99% | 3.51% | 9.49% | -119.64% | -121.42% |
| EPS Diluted | -15.30% | -5.30% | 1.62% | -176.04% | -136.24% |
| Normalized Diluted EPS | -7.99% | 3.51% | 9.49% | -113.32% | -115.11% |
| Average Basic Shares Outstanding | 4.98% | 9.46% | 14.83% | 20.85% | 19.71% |
| Average Diluted Shares Outstanding | 4.98% | 9.46% | 14.83% | 20.02% | 18.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |